This book provides cases and analyses of causes and consequences of difficulty in downsizing and exiting in the electronics industry during the "two lost decades" in Japan. Because of excess capacity in the industry, many electronics companies have been required for downsizing and exit since the 1990s. Exploiting corporate financial and segment datasets, it shows empirical evidence of misallocation of internal funds to "zombie" segments-intra-firm businesses suffering losses consecutively. The topics addressed in the book include the failure of Japanese corporate internal control systems, the lack of capital market pressure, employment protection, and misallocation of internal funds to businesses with few prospects. The last two decades indicate that the Japanese corporate governance systems have failed to resolve problems of excess capacity, as did US systems in the 1980s. Zombie lending is no more than one phase of the difficulty of downsizing and exit in response to excess capacity in the banking sector. Supported by both data analyses and rich anecdotal evidence, this book is highly recommended to readers who seek a convincing and comprehensive explanation of Japan's two lost decades from the points of view of difficulty in downsizing and exit. The authors' analyses have implications not only for accelerating downsizing and exit in corporate Japan, but also for the world economy.

This book, originally published in 1988, reviews the development of high technology industries at global and selected national and local levels, providing a unique insight into reasons for and consequences of such modern industrial development. It appraises government policies for assisting the development of this sector and focuses on the fact that high tech industry tends to be concentrated in particular regions of countries which attain the status of 'successful populations'. High technology industry seems to offer little benefit to declining manufacturing areas and the book offers explanations for these regional concentrations and assesses the likely consequences.

This book traces how abstract managerial ideas about maximizing production flexibility and employee freedom were translated into concrete, day-to-day practices at the Motorola plant in East Kilbride, UK. Using eyewitness accounts, the book describes how employees dealt with the increased freedom Motorola promoted amongst its employees, how employees adapted to managerial changes, specifically the elimination of large-scale management, and where the 'managerless' system came under strain. This book will be of essential reading for researchers, graduate students, and undergraduates interested in the areas of management studies, human resource management, and organizational studies, among others.

Originally published in 1988, this book explores how new technologies, industrial innovation and the growth of high technology industry have affected regional employment and economic change in different European countries. It discusses the factors which make some areas better suited than others to the development of the new industries, emphasising how fuctional integration and dependence upon highly-qualified manpower tend to concentrate these industries in particular locations. Attempts to encourage innovation and the development of high technology industry in old industrial areas are discussed, with particular reference to the role of large firms, training programmes and government policies.

With over 30,000 employees worldwide and products that range from refrigerators to cell phones, Haier is the largest consumer electronics manufacturer in China. This book traces this giant's path to success, from its early bleak years when the company director had to beg from the neighboring village head for money to pay bonuses to his employees to its achievement of placing sixth on Forbes Global's worldwide household appliance manufacturer in 2001. Much emphasis is given to Zhang Ruimin, Haier's chairman and CEO, for his pivotal role in the company's success. Explained is how Haier excelled where many other Chinese companies did not: a commitment to quality, service, and technology innovation, in addition to a global vision and a management style that is a blend of Jack Welch and Confucius.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech's improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech's science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech's founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, "Genentech" tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

This volume fills an important need for understanding about the interplay between China's intellectual property protection system and the potential for innovation in China's economy. Using examples from the pharmaceutical and biotech industries, the author suggests that, despite the widely documented challenges facing China's IPR protection system, the system has a demonstrable effect on innovation. The author suggests that China's patent system promotes innovation through economic incentives, soft factors of public encouragement, and intentional development strategies. This book is also useful as an overview of China's biotech and pharmaceutical sectors, offering a range of richly detailed case studies on China's industrial development strategies in these sectors. A number of important patent disputes between Chinese and foreign companies are also examined to useful effect. In the highly contentious policy world of intellectual property protection and pharmaceutical and biotech industry development, the volume offers a refreshing combination of detail and insight.'uPitman B. Potter, University of British Columbia, Canada'Yahong Li's pioneering study, Imitation to Innovation in China, breaks new ground in closely examining the extent to which the Chinese government's patent policies and patent activity by Chinese firms are influencing China's coming transformation from an imitation-oriented country to an innovation-oriented one. Her combination of theoretical and empirical approaches exploring the links between public policy, patenting activity and technological innovation (commercialization) is an important contribution to development studies, not just for China but for other newly innovative countries as well.'uWilliam O. Hennessey, Franklin Pierce Law Center, USA Following decades in which China's approach to technology has been to imitate, the country is now transforming itself to become innovation-oriented. This pioneering study examines whether patents play as similar a role in promoting innovation in China as they do in the West, exploring the interplay between patents and China's biotechnology and pharmaceutical industries in particular. The author argues for a stronger patent regime based on an extensive review of the technological capacity, R&D models, patent filings and litigations, and issues in patent law, which involve China's biotechnology and pharmaceutical industries. By comparing China with other developing countries and analyzing China's uniqueness in terms of its development stage, technological capacity and the strengths and weaknesses in its patent system, the author concludes that China is distinguished from the prevailing view that patents play a limited role in innovation in developing countries. The book also discusses whether and how patents can promote innovation in China's biotechnology and pharmaceutical industries, based on the study of market scale, R&D capacity, innovation model and patent legislation and cases.

The Committee on Finance of the United States Senate requested the Commission to examine the competitive conditions affecting certain industries that are developing and adopting new industrial biotechnology (IB) processes and products. IB was defined as the manufacture of liquid fuel and chemical products using enzymes, micro-organisms, or renewable resources. The application of IB can improve the efficiency of the industries and lead to the development of new products. Thus, this book focuses on U.S. liquid biofuel producers and firms in the U.S. chemical industry. An analysis of the current impact of IB on the U.S. economy is also provided. Industrial biotechnology (IB) activities in the U.S. by the chemical and liquid fuel industries increased substantially during the 2004-2007 period. Sales of U.S. produced bio-based products, for example, increased by over 30% during the period. As discussed in this book, much of this growth is accounted for by the ethanol and biodiesel industries, which are strongly supported by government tax incentives or mandatory use regulations, or both.

Transform your research into commercial biomedical products with this revised and updated second edition. Covering drugs, devices and diagnostics, this book provides a step-by-step introduction to the process of commercialization, and will allow you to create a realistic business plan to develop your ideas into approved biomedical technologies. This new edition includes: Over 25% new material, including practical tips on startup creation from experienced entrepreneurs. Tools for starting, growing and managing a new venture, including business planning and commercial strategy, pitching investors, and managing operations. Global real-world case studies, including emerging technologies such as regulated medical software and Artificial Intelligence (AI), offer insights into key challenges and help illustrate complex points. Tips and operational tools from established industry insiders, suitable for graduate students and new biomedical entrepreneurs.

High-tech businesses form a crucial part of entrepreneurial activity in some ways representing very typical examples of entrepreneurship, yet in some ways representing quite different challenges. The uncertainty in innovation and advanced technology makes it difficult to use conventional economic planning models, and also means that the management skills used in this area must be more responsive to issues of risk, uncertainty and evaluation than in conventional business opportunities.
While entrepreneurial courses do reflect the importance of high-tech businesses, they often lack the resources needed to teach this in a way that goes beyond standard how to start up a business courses whilst not focusing solely on theoretical models. This book specifically focuses on the mix of theory and practice needed to accurately inform students. Key topics covered include:
* uncertainty and innovation
* entrepreneurial finance
* marketing technological innovations
* high-tech incubation management.
Including case studies to give practical insights into genuine business examples, this comprehensive book has a distinctly real-world focus throughout. Edited by a multi-national team, it draws together leading writers and researchers from across Europe, and is therefore a must-read for all those involved in advanced entrepreneurship with specific interests in high-tech start-ups.

"Sony vs. Samsung" is business history at its best! It explores the divergent fortunes of these two electronics giants in the last decade and identifies the true reasons behind Sony's decline and Samsung's rise. Contrary to popular belief, Chang shows that success (or failure) does not simply arise from different strategies. Rather, it emerges from major decisions that are deeply rooted in the companies' organizational processes and their executives' political behavior. This book is a must-read for any senior executive. --Constantinos Markides
"Robert P. Bauman Professor of Strategic Leadership and Chairman,
Strategy Department, London Business School"

Sea-Jin Chang has produced that rarity in a business book--one that is as valuable to practicing managers as it is insightful to academic researchers. In this fascinating comparison of two modern global giants, he applies his high resolution research microscope to their changing fortunes by dissecting their contrasting strategies, and providing interesting insights into their divergent organizational processes and management practices. This is a very valuable contribution to the international business literature. It will end up in as many corporate boardrooms as faculty seminars.--Christopher A. Bartlett
"Thomas D. Casserly Professor Emeritus, Harvard Business School"

Sea-Jin Chang has written a fascinating comparison of Sony and Samsung that will be valuable to anyone interested in strategy, organizations or international business. The interwoven and very detailed case studies of two very different companies in overlapping industries illuminate problems such as adaptation to technological change (analog to digital), organizational flexibility and globalization. His attempt to analyze both strategic development and implementation is successful and very useful. Both academics and practitioners will learn a lot from this book.--Stephen J. Kobrin, "William Wurster Professor of Multinational Management, The Wharton School, University of Pennsylvania"

Refreshingly original and entertaining, this book analyzes major strategic decisions of Samsung and Sony and highlights organizational processes and top management leadership that have shaped their performances. This is a must-read for all executives who want to understand the strengths and weaknesses of Asian competitors. It also provides penetrating insights to other Asian companies with global ambitions.-- Myoung Woo Lee, "President and CEO
iriver"

PRAISE FOR Trading in the Zone

"Ari Kiev takes us inside the most successful trading firms of our time and shows us how those firms seek to improve performance through disciplined self analysis and structured goal management. His application of psychiatric tools to the short-term trading aspects of behavioral finance can give readers a competitive edge."–Charles A. Leeds Jr., CFA, Managing Member, Hermit Capital Management, LLC

"Kiev uses the powerful combination of his professional training as well as a unique vantage point inside the ropes at a market-moving, high-rolling hedge fund to deliver a fascinating analysis of a trader’s psyche. Although trading is widely acknowledged as an art, one that requires incredible innate intuition and feel for the markets, Kiev prescribes ‘getting into the zone’– a psychological state that one can create – for those aiming to achieve a higher level of performance. His anecdotes, case studies, interviews and tales of the ‘Master Trader’ are both instructive and tremendously insightful. A compelling read."–Ciaran T. O'Kelly, Head of Equity Trading, Salomon Smith Barney

"Trading in the Zone discusses the psychological considerations that serve to distinguish the most successful traders and portfolio managers from the majority of traders who are doomed to failure. Trading is so greatly influenced by emotions and discipline that not to have Ari’s insight and advice is a serious mistake."–Tom DeMark, author of The New Science of Technical Analysis

"I have been managing money for more than twenty years and I am happy to endorse Dr. Kiev’s principles, which have enhanced my performance and that of my traders over the past three years. Trading in the Zone will propel readers to the next level of trading success."–Jay Goldman, Hedge Fund Manager, J. Goldman & Co., L.P.

"Ari Kiev’s Trading in the Zone clearly and forcefully illustrates the mental discipline that will enable a stock trader to improve his performance."–Allan R. Tessler, Chairman and CEO, Jnet Enterprises

"Dr. Kiev works with professional traders, including some of the best traders in the country. In Trading in the Zone, he provides numerous case studies based on the market experiences of these traders, told both through narratives and their own words, in order to distill insights and lessons that should prove invaluable to professional and aspiring traders alike."–Jack Schwager, author of The Market Wizards and Stock Market Wizards

Master the design and operation of perfusion cell cultures with this authoritative reference. Discover the current state-of-the-art in the design and operation of continuous bioreactors, with emphasis on mammalian cell cultures for producing therapeutic proteins. Topics include the current market for recombinant therapeutic proteins, current industry challenges and the potential contribution of continuous manufacturing. Provides coverage of every step of process development and reactor operation, including small scale screening to lab-scale and scale-up to manufacturing scale. Illustrated through real-life case studies, this is a perfect resource for groups active in the cell culture field, as well as graduate students in areas such as chemical engineering, biotechnology, chemistry and biology, and to those in the pharmaceutical industry, particularly biopharma, biotechnology and food or agro industry.

What do CERN, smartphones, the iridium satellite network, the most popular app stores in the world, the biggest online game in the world, Moscow drivers, Seniors golfer Tony Johnstone, sufferers of rheumatoid arthritis and anyone who has their DNA sequenced have in common? They all rely on innovations that have come out of the technology cluster known as the Cambridge Phenomenon. This book, a follow-up to The Cambridge Phenomenon: 50 Years of Innovation and Enterprise, showcases what the Cambridge technology cluster has done for the world. The Cambridge Phenomenon: Global Impact reveals just how many of us, all around the globe, rely on Cambridge technology every day. This book tells the important, hidden story of how academic excellence and entrepreneurial endeavour have improved people's lives the world over. It is crucial reading for anybody interested in the ways successful businesses work, and the fundamental role of our great educational institutions in fostering that success.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech's improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech's science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech's founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, "Genentech" tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

The Silicon phenomenon was, is, and will be an extremely important phenomenon in the accelerated technological, scientific, and economic development of countries and regions. Silicon Valley North (SVN) is the high tech capital of Canada, the nation??'s most developed and dynamic technology sector, which includes multiple clusters in telecommunications, software, photonics, and life sciences. It gave birth to many well-known companies such as Corel, JDS Uniphase, Mitel, Newbridge Networks, Nortel Networks, Digital Equipment of Canada, just to mention a few. A lot of literature describes Silicon Valley and Silicon Alley in the US, Silicon Islands in Asia, and so on. Despite the quite evident importance of Silicon Valley North for the regional, national, and international technological development (especially when Nortel Networks and JDS Uniphase became global leaders in their fields and expanded in explosive fashion), this phenomenon is far from being well understood. Because of this, a book on the Canadian Silicon Valley is an exceptionally timely endeavor.
Silicon Valley North: A High-Tech Cluster of Innovation and Entrepreneurship is devoted to the multidimensional and multifaceted nature of SVN, its history, current state and future developments. The book offers a broad and deeply thematic analysis of one particular innovative cluster???Silicon Valley North. The reader will obtain expert insight into what SVN is all about by acquiring a comprehensive and "panoramic picture" of SVN within a single book. The reader will develop an accurate sense of what spurs high tech start-up companies in SVN toward their exceptional performances, and how to apply these insights to his or herunique regional context.

Scientists in the biotechnology sector have developed a vast array of products and procedures, including drugs, diagnostics, agricultural products and veterinary procedures. This is made possible through various intra- and inter-organizational collaborations between the academic and private sectors, and through the establishment of networks for learning. In Networks for Learning and Knowledge Creation in Biotechnology, Amalya Lumerman Oliver shows how, in many respects, the organizational structure of the industry parallels one of its most important innovations - recombinant DNA (rDNA). She shows how the concept of recombination can be used to explain a number of organizational elements, including biotechnology firms, the form of university-based spin-offs, scientific entrepreneurship, and trust and contracts in learning collaborations and networks. The result is a stimulating account of how multiple theoretical perspectives can be used to understand the structure of the biotechnology industry.

This is a full-length history of the Western Electric Company, which was the manufacturing arm of the Bell System. As manufacturer in the communications revolutions in the nineteenth and twentieth centuries, Western Electric made products that accelerated society's pace, such as telegraphs, telephones, an early computing machine, radios, radar and transistors. Western's history offers numerous examples of the difference between innovation and implementation. The aftermath of Western's 1882 acquisition by Bell Telephone, for instance, reveals vertical integration as a lengthy process rather than a single event. Ironically, although Western transformed business worldwide with innovations in areas such as quality control and industrial psychology, the company was slow to implement these innovations itself. Western's dual role as captive supplier for a regulated monopoly and as government contractor led to its most rapid change, in the area of civil rights.

In The Capacity to Innovate, Sarah Giest provides insight into the collaborative and absorptive capacities needed to provide public support to local innovation through cluster organizations. The book offers a detailed view of the vertical, multi-level, and horizontal dynamics in clusters and cluster policy and addresses how they are managed and supported. Using the biotechnology field as an example, Giest highlights challenges in the collaborative efforts of public bodies, private companies, and research institutes to establish a successful ecosystem of innovation in this sector. The book argues that cluster policy in collaboration with cluster organizations should focus on absorptive and collaborative capacity elements missing in the cluster context in order to improve performance. Currently, governments operate at different levels - from the local to the supranational - in order to support clusters, and cluster policies are often pursued alongside other programs, leading to uncoordinated efforts and ineffective cluster strategies. The Capacity to Innovate advocates for a coordinated effort by government and cluster organizations to support capacity elements lacking within the specific cluster context.

The comprehensive, practical guide to buying, selling, and merging technology companies

The Technology M&A Guidebook provides executives and entrepreneurs interested in acquiring or selling a technology company with everything they need to know about the entire M&A process, from identifying target companies or buyers to financial analysis, due diligence, tax issues, valuation, and legal considerations.

This book explores specific issues that are unique to technology M&A: assessing the impact of technology sector high-change rates; market-driven product development; company culture issues; engineers as managers and managers as engineers; consumer and technical product differences; technology marketing issues; intellectual property considerations; Internet interaction; and more. It also provides detailed analyses of factors involved in acquiring companies from different sectors, including:

• Semiconductor equipment and chip manufacturers
• PC/workstation and related hardware companies
• Software businesses
• Data networking and telecommunications firms
• Internet-related companies

Don’t enter the M&A process unprepared. Let The Technology M&A Guidebook help you beat the odds and make your sale or acquisition a complete success.

Manufacturing the Future: A History of Western Electric is the first full-length history of the Western Electric Company, the manufacturing arm of the Bell System. As a manufacturer in the communications revolutions in the nineteenth and twentieth centuries, Western Electric made new products such as telegraphs, telephones, an early computing machine, radios, radar, and transistors. The book demonstrates, through Western's 1882 acquisition by Bell Telephone, that vertical integration was a lengthy process rather than a single event. It also shows the coming of age of industrial psychology and describes the advent of civil rights in corporate America.

Digital Innovation for Healthcare in COVID-19 Pandemic: Strategies and Solutions provides comprehensive knowledge and insights on the application of information technologies in the healthcare sector, sharing experiences from leading researchers and academics from around the world. The book presents innovative ideas, solutions and examples to deal with one of the major challenges of the world, a global problem with health, economic and political dimensions. Advanced information technologies can play a key role in solving problems generated by the COVID-19 outbreak. The book addresses how science, technology and innovation can provide advances and solutions to new global health challenges. This is a valuable resource for researchers, clinicians, healthcare workers, policymakers and members of the biomedical field who are interested in learning how digital technologies can help us avoid and solve global disease dissemination.

Agricultural (or "green") biotechnology is a source of growing tensions in the global trading system, particularly between the United States and the European Union. Genetically modified food faces an uncertain future. The technology behind it might revolutionize food production around the world. Or it might follow the example of nuclear energy, which declined from a symbol of socioeconomic progress to become one of the most unpopular and uneconomical innovations in history.

This book provides novel and thought-provoking insights into the fundamental policy issues involved in agricultural biotechnology. Thomas Bernauer explains global regulatory polarization and trade conflict in this area. He then evaluates cooperative and unilateral policy tools for coping with trade tensions. Arguing that the tools used thus far have been and will continue to be ineffective, he concludes that the risk of a full-blown trade conflict is high and may lead to reduced investment and the decline of the technology. Bernauer concludes with suggestions for policy reforms to halt this trajectory--recommendations that strike a sensible balance between public-safety concerns and private economic freedom--so that food biotechnology is given a fair chance to prove its environmental, health, humanitarian, and economic benefits.

This book will equip companies, farmers, regulators, NGOs, academics, students, and the interested public--including both advocates and critics of green biotechnology--with a deeper understanding of the political, economic, and societal factors shaping the future of one of the most revolutionary technologies of our times.

Agricultural (or "green") biotechnology is a source of growing tensions in the global trading system, particularly between the United States and the European Union. Genetically modified food faces an uncertain future. The technology behind it might revolutionize food production around the world. Or it might follow the example of nuclear energy, which declined from a symbol of socioeconomic progress to become one of the most unpopular and uneconomical innovations in history. This book provides novel and thought-provoking insights into the fundamental policy issues involved in agricultural biotechnology. Thomas Bernauer explains global regulatory polarization and trade conflict in this area. He then evaluates cooperative and unilateral policy tools for coping with trade tensions. Arguing that the tools used thus far have been and will continue to be ineffective, he concludes that the risk of a full-blown trade conflict is high and may lead to reduced investment and the decline of the technology. Bernauer concludes with suggestions for policy reforms to halt this trajectory--recommendations that strike a sensible balance between public-safety concerns and private economic freedom--so that food biotechnology is given a fair chance to prove its environmental, health, humanitarian, and economic benefits. This book will equip companies, farmers, regulators, NGOs, academics, students, and the interested public--including both advocates and critics of green biotechnology--with a deeper understanding of the political, economic, and societal factors shaping the future of one of the most revolutionary technologies of our times.

This book integrates a science and business approach to provide an introduction and an insider view of intellectual property issues within the biotech industry, with case studies and examples from developing economy markets. Broad in scope, this book covers key principles in pharmaceutical, industrial, and agricultural biotechnology within four parts. Part 1 details the principles of intellectual property and biotechnology. Part 2 covers plant biotechnology, including biotic and abiotic stress tolerance, GM foods in sustainable agriculture, microbial biodiversity and bioprospecting for improving crop health and productivity, and production and regulatory requirements of biopesticides and biofertilizers. The third part describes recent advances in industrial biotechnology, such as DNA patenting, and commercial viability of the CRISPR/Cas9 system in genome editing. The final part describes intellectual property issues in drug discovery and development of personalized medicine, and vaccines in biodefence. This book is an ideal resource for all postgraduates and researchers working in any branch of biotechnology that requires an overview of the recent developments of intellectual property frameworks in the biotech sector.